Participating in the above panel discussion is Dr Hua Mu, Senior Vice President, Clinical Research & Development, Hutchison MediPharma, China. He will be speaking at Pharma Trials World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
Dr. Mu joined Hutchison MediPharma in 2010 as the Senior Vice President, Clinical Research & Development. He has over 16 years of clinical research and development experience focusing on oncology, having held medical and clinical leadership positions at several leading global pharmaceutical and biotech companies including Roche, Abraxis, Biogen Idec and most recently, Genentech. His industrial experience spans over early to late stage development, and medical affairs of cytotoxic agents, small molecules, and monoclonal antibodies for cancer and autoimmune diseases. Dr. Mu has extensive experience in leading cross-functional teams and clinical R&D organizations, dealing with regulatory authorities and bringing drug candidates through the development process to market. He was involved in the development of a number of successful oncology drugs including XelodaÂ®, AbraxaneÂ®, and AvastinÂ®. Dr. Mu received his medical degree from West China University of Medical Sciences and his Ph.D. degree from the University of California at Berkeley. Prior to joining the industry, Dr. Mu was a Senior Fellow at Departments of Medicine of the University of Washington and the University of California at San Francisco.
Dr Hua Mu will be discussing about the following issues:
Panel: Optimising clinical trials in Asian powerhouses – India & China
1. Overcoming regulatory constraints in the two largest Asian markets to fast-track clinical trials
2. Aligning clinical development, medical affairs and regulatory affairs to enhance your clinical trial design
3. Determining key factors for a successful partnership between pharmas, biotechs and CROs